What is the solution of Red West to the red of China?

Reed Sive, developed by the American Gilead Science Company. Reed Sive has reported positive results in many countries for many days and caused European and American stock markets to rise sharply. The Chinese team published a clinical trial report on the treatment of severe coronavirus heart disease patients with redoxir. The conclusions reached are quite different from those disclosed by US agencies. In this regard, Chinese scholars pointed out that the evaluation standards of the two countries are different. Earlier, Ridsivir was called the people’s hope by the netizens in the Chinese network.

According to Lianhe Zaobao today, citing official Chinese news, saying that Chinese scholars responded to Rydsey West’s conclusion that China and the United States have very different conclusions. They think that the evaluation criteria are different. The report cited surging news that on the evening of the 29th, the internationally renowned medical journal. “The Lancet” published the results of a clinical trial of the new coronavirus pneumonia antiviral drug Redoxir conducted by the Chinese team. The results of the study showed that no statistically significant clinical benefit was observed in the combination of Remdesivir with standard therapy compared with standard therapy. According to Professor Cao Bin of the China-Japan Friendship Hospital and Capital Medical University, who was in charge of the study. “This trial found that, although Remdesivir is safe and well-tolerated. It has no significant benefits compared to placebo. ”

The report said that this is very different from the information disclosed by US research institutions. On the same day, Gilead Sciences, Inc. A research and development pharmaceutical company of Redisive also issued a statement saying that the National Institute of Allergy and Infectious Diseases (NIAID) has made active research on Redisive The data. “We understand that the trial has reached the main endpoint, and NIAID will provide detailed information at the upcoming briefing.”

The National Institute of Allergy and Infectious Diseases is one of the 27 institutes and centres under the National Institutes of Health (NIH) under the US Department of Health and Human Services.

According to the report, in response to the question that the conclusions of the clinical trials between China and the United States are quite different. Cao Bin, the head of the Chinese clinical trial of Red West, responded to the reporter: “This is two different studies, and the evaluation criteria are different.” Xiang Pengpai reporter said, for example, assuming that one person is 1.75 meters tall and the other person is 1.7499 meters tall, can the first person reach a higher-conclusion? If the standard is accurate to 1 mm, then the first person is higher, if 1 mm is neglected, then the two are the same height. The reason is that the evaluation endpoint is different. According to Cao Bin. “In the beginning, we imagined Ridewell as the seed of Tsinghua Peking University, but in fact, he couldn’t get on, and the parents demanded him too much.

It is understood that this study conducted by the Chinese team is the first randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of intravenous redoxir on adult severely hospitalized patients with new coronary pneumonia. The experiment was conducted in 10 hospitals in Wuhan, Hubei. The study was terminated without reaching the predetermined sample size.